| Bioactivity | Inaxaplin (VX-147) is an orally active apolipoprotein L1 (APOL1) function inhibitor (WO2020131807, compound 2). Inaxaplin can be used for the research of kidney disease[1]. | ||||||||||||
| Target | APOL1 | ||||||||||||
| Invitro | Inaxaplin is an apolipoprotein L1 function inhibitor[1]. | ||||||||||||
| Name | Inaxaplin | ||||||||||||
| CAS | 2446816-88-0 | ||||||||||||
| Formula | C21H18F3N3O3 | ||||||||||||
| Molar Mass | 417.38 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. WO2020131807 |
Inaxaplin
CAS: 2446816-88-0 F: C21H18F3N3O3 W: 417.38
Inaxaplin (VX-147) is an orally active apolipoprotein L1 (APOL1) function inhibitor (WO2020131807, compound 2). Inaxapli
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.